NicOx Moves Diabetes Drug into Phase II
Posted on: Thursday, 27 July 2006, 12:01 CDT
Following promising results in previous trials, NicOx SA has opted to move NCX 4016 forward in clinical development as a novel insulin sensitizing agent for the treatment of type 2 diabetes.
The company expects to initiate two phase II studies within the next six months. The trials will have the goal of confirming the mechanism of action of NCX 4016 as an insulin sensitizer and demonstrating a clinical benefit in the treatment of type 2 diabetes.
The decision to initiate this clinical program follows the encouraging results obtained in type 2 diabetes patients in three previously announced trials for NCX 4016 in the cardiometabolic setting. A good safety and tolerability profile has also been demonstrated in long-term treatment.
The first study is projected to be a single-center, cross-over trial, designed to confirm the mechanism of action of NCX 4016 as an insulin sensitizing agent using a hyperinsulinemic euglycemic clamp. The second trial is projected to be a placebo and active controlled, double blind, parallel study, aiming to demonstrate a clinical benefit for NCX 4016 through the measurement of HbA1c and blood glucose in the fasting state and after meals.
"In light of the type 2 diabetes pandemic that is appearing in the developed world, there is a clear need for a new class of oral treatments which could counteract insulin resistance through an alternative mechanism," said Maarten Beekman, vice president of clinical development at NicOx. "There is a solid scientific rationale supporting the development of NCX 4016 as an insulin sensitizing agent, based on the known effects of nitric oxide and salicylate and the recent finding that NCX 4016 releases higher and more sustained levels of salicylate than previously thought."
Source: Datamonitor
Related Articles
- Uroplasty Highlights Results From Clinical Study on Macroplastique(R) for the Treatment of Stress Urinary Incontinence
- Aradigm Announces Data Showing No Occurrence of Primary Lung Cancer in Patients Treated With AERx(R) Insulin Diabetes Management System (iDMS)
- Bentley Pharmaceuticals Announces Completion of Treatment in Phase II India Clinical Study in Type 2 Diabetes and Preliminary Clinical Results
- Sirtris Pharmaceuticals' SIRT1 Activator Controls Glucose As Well As a DPP-4 Inhibitor in a Pre-Clinical Model of Type 2 Diabetes
- NicOx to Move NCX 4016 Forward in Phase 2 for Diabetes
- For the Clinical Management and Treatment of Psychiatric Disorders Once Diagnosed the New Guide a Clinical Guide to the Diagnosis and Treatment of Mental Disorders May Be of Assistance
- Differential Association of Basal and Postprandial Plasma Ghrelin With Leptin, Insulin, and Type 2 Diabetes
- Amylin Pharmaceuticals Announces FDA Approval of SYMLIN(R) for Insulin-Using Type 2 and Type 1 Diabetes
- NicOx Announces NCX 4016 More Effective Than Aspirin at Preventing Platelet Activation in Diabetes in Phase IIa Study
- NicOx Announces Full Patient Enrollment in Phase II Trial of NCX 4016 in PAOD
 |
 |
User Comments (0)
RSS Feeds